Although the Food and Drug Administration FDA approved labeling for the antihistamine, promethazine, already contained a warning about the risk of serious breathing problems when the drug is used by children, a number of deaths in children under two years of age has prompted Emergency Alerts to both healthcare professionals and consumers to advise of a label change that contains “strengthened warnings.â€
The Alert released as part of the Patient Information Sheet states that:
“Medications containing promethazine hydrochloride (HCl) should not be used for children less than two years old because of possible breathing problems. This includes promethazine HCl in any form: syrups, suppositories, tablets, or injectables. Cases of breathing problems, some causing death, have been reported to the FDA when the drug was used in children less than two years old.â€
(more…)

